Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.65 |
| ▸ | RAB9A | P51151 | 8/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3468613 | 1.00 | NPC1 (0.65) | NPC1RAB9AMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL14046555 | 0.90 | NPC1 (0.74) | NPC1RAB9AMAPTSMN1; SMN2HCRTR1 | |
| Fumaric Acid SCHEMBL3468731 | 0.86 | NPC1 (0.61) | NPC1RAB9AMAPTSMN1; SMN2HCRTR1 | |
| Fumaric Acid SCHEMBL3468728 | 0.86 | NPC1 (0.61) | NPC1RAB9AMAPTSMN1; SMN2HCRTR1 | |
| SCHEMBL23269717 | 0.85 | NPC1 (0.75) | NPC1RAB9AMAPTSMN1; SMN2HCRTR1 | |
| SCHEMBL27727271 | 0.83 | NPC1 (0.74) | NPC1RAB9AMAPTSMN1; SMN2HCRTR1 | |
| Fumaric Acid SCHEMBL3468680 | 0.80 | MAPT (0.52) | NPC1RAB9AMAPTSMN1; SMN2ALOX15 | |
| Fumaric Acid SCHEMBL3468677 | 0.80 | MAPT (0.52) | NPC1RAB9AMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL6125241 | 0.79 | NPC1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2CNR2 | |
| Hydrochloric Acid SCHEMBL3468835 | 0.78 | NPC1 (0.56) | NPC1RAB9AMAPTSMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | claimed |
| JP-2009531376-A | — | — | 2009-09-03 | — | — | JP | claimed |
| CN-101410385-A | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-04-15 | — | — | CN | claimed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | claimed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-1999120-B1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-06-27 | — | — | EP | disclosed |
| CN-101410385-B | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC | 2011-08-24 | — | — | CN | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| CN-101410385-A | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-04-15 | — | — | CN | disclosed |
| EP-1999120-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | NPC1 3350/4885RAB9A 3540/4885MAPT 1467/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | NPC1 3474/4885RAB9A 3387/4885MAPT 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.